Keyword
- Patent filing & prosecution
- Invalidation • Infringement • FTO
- Patent listing & term extensions
- Pharma • Biosimilars • Chemical materials
Biography
- Justin HWANG is a partner at NAM IP Group covering pharmaceuticals, biotechnology, chemistry and materials. His practice spans small-molecule and antibody drugs, pharmaceutical manufacturing, organic, inorganic and polymer materials, semiconductor processes, OLEDs and batteries. As a former part leader in Celltrion's IP Strategy Team, he brings direct experience aligning biopharmaceutical IP with corporate business priorities.
- He handles Korean filings for overseas pharmaceutical, biotech, chemical and materials companies on drug compounds and formulations, resins and polymers, etching and deposition materials, battery electrode binders and solid electrolytes. His experience also includes Korean and international prosecution for resins and electronic materials, invalidity and FTO opinions, and invalidation trials involving chemical compositions and medicines.
- In life sciences, he has handled follow-on patent filings and prosecution to extend protection for liver disease treatments, pharmaceutical searches and mapping, patent listing and term extensions. He has also worked on invalidity, infringement and preliminary injunction proceedings in Korea, Japan, the US, Canada and Europe to support earlier biosimilar launches, connecting prosecution, regulatory protection and disputes.
- His principal services are prosecution, FTO and invalidity analysis, appeals and litigation, and pharmaceutical patent listing and term extensions. Combining in-house and international disputes experience, he supports IP strategies from R&D protection through product launch and dispute management.
Qualification
- Admitted to Patent Bar (2009)
- KPAA (Korean Patent Attorneys Association)
Professional Expertise
- Practice Areas
- Inventor consultations, patent filings and office action responses
- Patent invalidation and scope-of-rights trials
- Patent infringement litigation and preliminary injunctions
- Pharmaceutical patent listing and patent term extensions
- Patent searches, mapping and patent-based technology transfer
- Technical Expertise
- Small-molecule drug compounds and antibody drugs, including biosimilars
- Drug manufacturing: culture, purification and formulation; administration methods; medical instruments
- Semiconductor process materials: resists, precursors, deposition and etching; electronic materials
- Battery binders and solid electrolytes; solar and fuel cells; OLED emitters
- Organic and polymer materials, resin compositions and inorganic materials
- Water treatment compositions and systems; 3D printing materials
Contact
- Tel: 02-6714-1201
- Email: syhwang@nampat.co.kr
- Language: Korean / English / Japanese
Professional Profile
- Representative Experience
- Invalidity, infringement and preliminary injunction proceedings in Korea, Japan, the US, Canada and Europe for earlier biosimilar launches
- Korean follow-on filings and prosecution to extend patent protection for liver disease treatments
- Invalidity and freedom-to-operate opinions and invalidation trials for chemical compositions and drugs
- Patent-based technology transfer involving inorganic materials
- Hub filing matters for Japanese clients
- Pharmaceutical patent searches, mapping, listing and term extensions
- Professional Background
- [Career]Partner, NAM IP Group (2024–present)
- Senior Patent Attorney, NAM & NAM (2019–2023)
- Part Leader, IP Strategy Team, Celltrion (2017–2018)
- [Education]Seoul National University, B.S., Chemical and Biological Engineering (2010)
- [Qualifications]Korean Patent Attorney (2009; 46th qualifying examination)
- [Activities]Reviewer, first stage of the 47th Korean Patent Attorney Examination (2010)
- Patent training for SMEs (2012)
- Technology demand survey, Foundation of Agricultural Technology Commercialization and Transfer (2014)
- Member, Korean Patent Attorneys Association (KPAA)